Drugs / favezelimab/pembrolizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05064059 | Nov 2021 → Aug 2024 | colorectal cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | favezelimab/pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05064059 ↗ |
| Route | Intravenous | “Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion” NCT05064059 ↗ |